Souders Financial Advisors Trims Position in Novo Nordisk A/S $NVO

Souders Financial Advisors cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 24.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,347 shares of the company’s stock after selling 4,309 shares during the period. Souders Financial Advisors’ holdings in Novo Nordisk A/S were worth $921,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Revolve Wealth Partners LLC boosted its position in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Novo Nordisk A/S by 6.0% during the first quarter. Bank of New York Mellon Corp now owns 839,802 shares of the company’s stock valued at $58,316,000 after purchasing an additional 47,804 shares in the last quarter. Penserra Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 29.7% during the first quarter. Penserra Capital Management LLC now owns 7,831 shares of the company’s stock valued at $543,000 after purchasing an additional 1,794 shares in the last quarter. U.S. Capital Wealth Advisors LLC boosted its position in shares of Novo Nordisk A/S by 26.6% during the first quarter. U.S. Capital Wealth Advisors LLC now owns 8,773 shares of the company’s stock valued at $609,000 after purchasing an additional 1,843 shares in the last quarter. Finally, Crossmark Global Holdings Inc. boosted its position in shares of Novo Nordisk A/S by 1.6% during the first quarter. Crossmark Global Holdings Inc. now owns 51,937 shares of the company’s stock valued at $3,607,000 after purchasing an additional 841 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on NVO. BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. BMO Capital Markets reissued a “market perform” rating and issued a $55.00 target price (up from $50.00) on shares of Novo Nordisk A/S in a report on Tuesday, October 14th. Hsbc Global Res raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 1st. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Finally, Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $59.20.

Novo Nordisk A/S Trading Up 0.4%

Shares of NYSE:NVO opened at $48.43 on Thursday. The company has a market cap of $216.24 billion, a P/E ratio of 13.30, a PEG ratio of 2.33 and a beta of 0.68. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $112.52. The stock’s fifty day moving average price is $55.73 and its 200-day moving average price is $61.69.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.12. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.